- Program Integration and Management This P01 grant application consists of four investigator-initiated and led research projects at geographically distinct locations interacting with two core resources constructed around a theme of prostate cancer metastasis. Our P01 joins multi-disciplinary expertise and state-of-the art research projects with commitments from a leading institution to produce successful advances in our understanding of the drivers of prostate cancer metastasis. The projects and cores proposed in this application are highly integrated and are poised to take maximum advantage of the program project grant mechanism to achieve its overall goals. This multi-center structure is both the greatest strength of this P01 and yet is also a challenge. Administration will be especially important in that it will provide the coordinated management structure, allowing each participating institution to interact and communicate effectively. A flexible, highly interactive administrative structure is proposed whereby research plans can be collaboratively developed and progress can be continuously monitored. The overall objective of Program Integration and Management is to provide leadership, direction, coordination, and administrative services for the purposes of enhancing research productivity and maintaining a highly effective research environment. An important goal will be to foster the exchange of ideas and promote collaboration through interactions between the Project Leaders, Core Directors and all members of the research groups. In order to achieve the overall objective, Program Integration & Management will focus on the following primary objectives: 1) Leadership; 2) Site Coordination & Administrative Management; 3) Communications Management and 4) Scientific Oversight. The research environment so created will provide an exceptional opportunity by recasting a potential weakness- the multiple participating institutions - into a significant strength, namely, a remarkably broad and deep coalition of prostate cancer investigators with a demonstrated history of commitment and accomplishment in the study of prostate cancer metastasis.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Cedars-Sinai Medical Center
Los Angeles
United States
Zip Code
Farach-Carson, Mary C; Lin, Sue-Hwa; Nalty, Theresa et al. (2017) Sex Differences and Bone Metastases of Breast, Lung, and Prostate Cancers: Do Bone Homing Cancers Favor Feminized Bone Marrow? Front Oncol 7:163
Stewart, Paul A; Khamis, Zahraa I; Zhau, Haiyen E et al. (2017) Upregulation of minichromosome maintenance complex component 3 during epithelial-to-mesenchymal transition in human prostate cancer. Oncotarget 8:39209-39217
Masko, Elizabeth M; Alfaqih, Mahmoud A; Solomon, Keith R et al. (2017) Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model. Prostate 77:446-457
Jolly, Mohit Kumar; Boareto, Marcelo; Debeb, Bisrat G et al. (2017) Inflammatory breast cancer: a model for investigating cluster-based dissemination. NPJ Breast Cancer 3:21
Alfaqih, Mahmoud A; Allott, Emma H; Hamilton, Robert J et al. (2017) The current evidence on statin use and prostate cancer prevention: are we there yet? Nat Rev Urol 14:107-119
Guan, Yang; Zhang, Yi; Xiao, Li et al. (2017) Improving Therapeutic Potential of Farnesylthiosalicylic Acid: Tumor Specific Delivery via Conjugation with Heptamethine Cyanine Dye. Mol Pharm 14:1-13
Nandana, Srinivas; Tripathi, Manisha; Duan, Peng et al. (2017) Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis. Cancer Res 77:1331-1344
Brennen, W Nathaniel; Zhang, Baohui; Kulac, Ibrahim et al. (2017) Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. Oncotarget 8:46710-46727
Tighiouart, Mourad; Cook-Wiens, Galen; Rogatko, André (2017) A Bayesian adaptive design for cancer phase I trials using a flexible range of doses. J Biopharm Stat :1-13
Tighiouart, Mourad; Li, Quanlin; Rogatko, André (2017) A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials. Stat Med 36:280-290

Showing the most recent 10 out of 208 publications